L Eric Huang

List of Publications by Year
in descending order

51 papers	6,851 citations	159358 30 h-index	182168 51 g-index
52 all docs	52 docs citations	52 times ranked	7829 citing authors

#	Article	IF	Citations
1	Ubiquitination of hypoxia-inducible factor requires direct binding to the Î²-domain of the von Hippelâ€“Lindau protein. Nature Cell Biology, 2000, 2, 423-427.	4.6	1,423
2	Activation of Hypoxia-inducible Transcription Factor Depends Primarily upon Redox-sensitive Stabilization of Its Î± Subunit. Journal of Biological Chemistry, 1996, 271, 32253-32259.	1.6	1,069
3	HIF-1Î± induces cell cycle arrest by functionally counteracting Myc. EMBO Journal, 2004, 23, 1949-1956.	3.5	581
4	Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18727-18732.	3.3	529
5	HIF-1Î± Induces Genetic Instability by Transcriptionally Downregulating MutSÎ± Expression. Molecular Cell, 2005, 17, 793-803.	4.5	332
6	Differential Gene Up-Regulation by Hypoxia-Inducible Factor-1Î± and Hypoxia-Inducible Factor-2Î± in HEK293T Cells. Cancer Research, 2005, 65, 3299-3306.	0.4	282
7	Inhibition of Hypoxia-inducible Factor 1 Activation by Carbon Monoxide and Nitric Oxide. Journal of Biological Chemistry, 1999, 274, 9038-9044.	1.6	277
8	Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes and Development, 2001, 15, 2520-2532.	2.7	275
9	Hypoxia-inducible Factor and Its Biomedical Relevance. Journal of Biological Chemistry, 2003, 278, 19575-19578.	1.6	274
10	Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood, 2008, 111, 3131-3136.	0.6	158
11	Hypoxia-induced genetic instabilityâ€”a calculated mechanism underlying tumor progression. Journal of Molecular Medicine, 2007, 85, 139-148.	1.7	128
12	Carrot and stick: HIF-Î± engages c-Myc in hypoxic adaptation. Cell Death and Differentiation, 2008, 15, 672-677.	5.0	128
13	Molecular Mechanism of Hypoxia-inducible Factor 1Î±-p300 Interaction. Journal of Biological Chemistry, 2001, 276, 3550-3554.	1.6	118
14	The phosphorylation status of PAS-B distinguishes HIF-1Î± from HIF-2Î± in NBS1 repression. EMBO Journal, 2006, 25, 4784-4794.	3.5	111
15	Suppression of Hypoxia-inducible Factor 1Î± (HIF-1Î±) Transcriptional Activity by the HIF Prolyl Hydroxylase EGLN1. Journal of Biological Chemistry, 2005, 280, 38102-38107.	1.6	92
16	Hypoxia-Inducible Factor-1 Transactivates Transforming Growth Factor-Î²3 in Trophoblast. Endocrinology, 2004, 145, 4113-4118.	1.4	84
17	Tumor suppressor p53 represses transcription of RECQ4 helicase. Oncogene, 2005, 24, 1738-1748.	2.6	75
18	Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood, 2006, 107, 916-923.	0.6	73

#	ARTICLE	IF	CITATIONS
19	Erythropoietin gene regulation depends on heme-dependent oxygen sensing and assembly of interacting transcription factors. Kidney International, 1997, 51, 548-552.	2.6	64
20	Leuâ€574 of human HIFâ€1Î± is a molecular determinant of prolyl hydroxylation. FASEB Journal, 2004, 18, 1028-1030.	0.2	62
21	A New Look at Rho GTPases in the Cell Cycle: Their Role in Kinetochore-Microtubule Attachment. Cell Cycle, 2004, 3, 853-855.	1.3	58
22	Friend or foeâ€”IDH1 mutations in glioma 10 years on. Carcinogenesis, 2019, 40, 1299-1307.	1.3	58
23	HIF-1Î± Confers Aggressive Malignant Traits on Human Tumor Cells Independent of Its Canonical Transcriptional Function. Cancer Research, 2011, 71, 1244-1252.	0.4	56
24	Hypoxic Suppression of the Cell Cycle Gene<i>CDC25A</i>in Tumor Cells. Cell Cycle, 2007, 6, 1919-1926.	1.3	54
25	Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1Î±. Carcinogenesis, 2009, 30, 1768-1775.	1.3	47
26	Dynamic Balancing of the Dual Nature of HIF-1alpha for Cell Survival. Cell Cycle, 2004, 3, 851-852.	1.3	41
27	An Essential Role of the HIFâ€1Î±â€“câ€Myc Axis in Malignant Progression. Annals of the New York Academy of Sciences, 2009, 1177, 198-204.	1.8	35
28	HIF-1Î± Mediates Tumor Hypoxia to Confer a Perpetual Mesenchymal Phenotype for Malignant ProgressionA presentation from the Keystone Symposium on Epithelial Plasticity and Epithelial-to-Mesenchymal Transition, Vancouver, British Columbia, Canada, 21 to 26 January 2011.. Science Signaling, 2011, 4, pt4.	1.6	34
29	Leu-574 of HIF-1Î± Is Essential for the von Hippel-Lindau (VHL)-mediated Degradation Pathway. Journal of Biological Chemistry, 2002, 277, 41750-41755.	1.6	33
30	Genetic Instability: The Dark Side of THE Hypoxic Response. Cell Cycle, 2005, 4, 881-882.	1.3	28
31	Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element. Acta OncolÃ³gica, 2006, 45, 317-324.	0.8	28
32	CITED2 controls the hypoxic signaling by snatching p300 from the two distinct activation domains of HIF-1Î±. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 2008-2016.	1.9	28
33	How HIF-1Î± Handles Stress. Science, 2013, 339, 1285-1286.	6.0	18
34	Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma. Biomedicines, 2022, 10, 246.	1.4	18
35	Requirement of evading apoptosis for HIF-1Î±-induced malignant progression in mouse cells. Cell Cycle, 2011, 10, 2364-2372.	1.3	16
36	Intermittent Induction of HIF-1Î± Produces Lasting Effects on Malignant Progression Independent of Its Continued Expression. PLoS ONE, 2015, 10, e0125125.	1.1	14

#	ARTICLE	IF	CITATIONS
37	The Impact of Hypoxia and Mesenchymal Transition on Glioblastoma Pathogenesis and Cancer Stem Cells Regulation. World Neurosurgery, 2016, 88, 222-236.	0.7	14
38	Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenaseâ€“mutant glioma. Journal of Neurosurgery, 2018, 130, 56-66.	0.9	14
39	Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential. Journal of Neuro-Oncology, 2020, 146, 427-437.	1.4	14
40	From antiangiogenesis to hypoxia: current research and future directions. Cancer Management and Research, 2010, 3, 9.	0.9	13
41	Complex role of HIF in cancer: the known, the unknown, and the unexpected. Hypoxia (Auckland, N Z), 2014, 2, 59.	1.9	11
42	Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis. Acta Neuropathologica, 2018, 135, 285-298.	3.9	10
43	von Hippel-Lindau protein adjusts oxygen sensing of the FIH asparaginyl hydroxylase. International Journal of Biochemistry and Cell Biology, 2011, 43, 795-804.	1.2	9
44	The neural stem-cell marker CD24 is specifically upregulated in IDH-mutant glioma. Translational Oncology, 2020, 13, 100819.	1.7	9
45	IDH1R132H is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment. Oncotarget, 2018, 9, 35100-35113.	0.8	9
46	Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma. Cells, 2021, 10, 2116.	1.8	8
47	Targeting HIF-Î±: when a magic arrow hits the bull's eye. Drug Discovery Today, 2004, 9, 869.	3.2	2
48	Can Irradiated Tumors Take NO for an Answer?. Molecular Cell, 2007, 26, 157-158.	4.5	2
49	An Efficient Way of Studying Proteinâ€“Protein Interactions Involving HIF-Î±, c-Myc, and Sp1. Methods in Molecular Biology, 2013, 1012, 77-84.	0.4	2
50	In Vivo Manipulation of HIF-1Î± Expression During Glioma Genesis. Methods in Molecular Biology, 2018, 1742, 227-235.	0.4	1
51	From antiangiogenesis to hypoxia: current research and future directions. Cancer Management and Research, 0, , 9.	0.9	0